Maiwei Biotech Investor Relations Activity Record List (2024/09/01)
Legal Opinion of Beijing Zhide (Shanghai) Law Firm on the 2024 Third Extraordinary General Meeting of Shareholders of Maiwei (Shanghai) Biotechnology Co., Ltd.
Announcement of Resolutions of the 2024 Third Extraordinary General Meeting of Shareholders of Maiwei Biotech
Haitong Securities Co., Ltd.\'s 2024 semi-annual follow-up report on the continuous supervision of Maiwei (Shanghai) Biotechnology Co., Ltd.
Maiwei Biotech 2024 Semi-Annual Report
Notice of Maiwei Biotech on convening the 3rd Extraordinary General Meeting of Shareholders in 2024
Maiwei Biotech\'s 2024 “Improve Quality, Increase Efficiency, and Reward” Action Plan
Summary of Maiwei Biotech\'s 2024 Semi-Annual Report
Announcement of Resolutions of the 12th Meeting of the 2nd Supervisory Board of Maiwei Biotech
Maiwei Biotech\'s special report on the storage and actual use of funds raised in the 2024 semi-year
Maiwei Biotech 2024 3rd Extraordinary General Meeting of Shareholders Meeting Information
Mabwell: Meiwei Biotech voluntarily disclosed the announcement that the Phase III clinical study of 9MW2821 combined with PD-1 monoclonal antibody for first-line treatment of urothelial carcinoma has obtained approval from the CDE.
Meiwei Biotech voluntarily disclosed the announcement that the Phase III clinical study of 9MW2821 combined with PD-1 monoclonal antibody for first-line treatment of urothelial carcinoma has obtained approval from the CDE.
Maivi Bioscience voluntarily discloses the announcement regarding the phase III clinical study of 9MW2821 for the treatment of cervical cancer approved by the CDE.
Meiwei Biopharmaceutical voluntarily disclosed the announcement on the inclusion of 9MW2821 for the indication of urothelial carcinoma into breakthrough therapy drugs.
Announcement of Maiwei Bio's increase in credit and financing amount applications to financial institutions for the 2024 fiscal year.
The verification opinion on the change of part of the fundraising special account and the re-signing of the four-party regulatory agreement by Maiwei (Shanghai) biotechnology Co., Ltd., submitted by Haitong Securities Co., Ltd.
Announcement from Maiwei Biology regarding its wholly-owned subsidiary's signing of a licensing agreement with Runjia Pharmaceutical.
Announcement of resolutions of the 11th meeting of the second session of the supervisory board of Maiwei Biology.
Announcement on the change of the special account for raising funds and the re-signing of the quadrilateral supervision agreement by Maiwei Biology.
No Data
No Data